Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20542017 | 0.82 | AHR (0.45) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL30579387 | 0.82 | AHR (0.45) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL20558099 | 0.82 | CDK1 (0.42) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL20541790 | 0.79 | CDK1 (0.61) | CDK1CDK5CDK5R1NPC1KDM4E | |
| SCHEMBL2315980 | 0.79 | CDK2 (0.50) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL20557747 | 0.78 | CDK1 (0.43) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL2315103 | 0.78 | AHR (0.58) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL20542056 | 0.77 | CDK5 (0.44) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL24966401 | 0.77 | CDK5 (0.42) | CDK1CDK5CDK5R1CCNB2CCNB1 | |
| SCHEMBL2358698 | 0.76 | CCNE2 (0.56) | CDK1CDK5CDK5R1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3612030-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Kyn Therapeutics (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110831600-A | Indole AHR inhibitors and uses thereof | 金恩医疗公司 | 2020-02-21 | — | — | CN | disclosed |
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| WO-2018195397-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2018-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327411-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | CDK1 2497/4885CDK5 1931/4885CDK5R1 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.